Early behavioral screening for antidepressants and anxiolytics

Early preclinical behavioral testing is an essential stage during the development of substances with potential antidepressant and/or anxiolytic activity. With the growing cost of drug development, optimal research strategies are needed to detect potential new treatments with high efficacy and minimal side effects and to confirm in vitro pharmacological studies. In the following article, we present simple rodent tests used for early behavioral testing for antidepressant-like and anxiolytic-like activity. Unpublished results from our laboratory are discussed with reference to published data to illustrate the predictive validity of several behavioral screening tests.